61272-39-7

Usage

Uses

Used in Pharmaceutical Industry:
1-CHLORO-3-CYCLOHEXYLAMINO-PROPAN-2-OL is used as a medication for the treatment of myasthenia gravis. It functions by inhibiting the enzyme acetylcholinesterase, which leads to an increase in the levels of the neurotransmitter acetylcholine at the neuromuscular junctions. This action helps to improve muscle strength and function in patients suffering from myasthenia gravis.
However, it is important to note that the use of 1-CHLORO-3-CYCLOHEXYLAMINO-PROPAN-2-OL may also result in side effects such as nausea, vomiting, and diarrhea. Despite these potential side effects, it remains an important medication in the management of myasthenia gravis, providing a valuable treatment option for those affected by this condition.

InChI:InChI=1/C9H18ClNO/c10-6-9(12)7-11-8-4-2-1-3-5-8/h8-9,11-12H,1-7H2

Upstream product

• 108-91-8 cyclohexylamine 
• 106-89-8 epichlorohydrin 

Downstream Products

• 100246-85-3 bis-(3-chloro-2-hydroxy-propyl)-cyclohexyl-amine 
• 76226-38-5 1-Cyclohexylamino-3-(5-pyridin-4-yl-4-p-tolyl-4H-[1,2,4]triazol-3-ylsulfanyl)-propan-2-ol 
• 116196-04-4 1-Cyclohexyl-3-trimethylsilanyloxy-azetidine 
• 13156-01-9 1-cyclohexyl-azetidin-3-ol 
• 13391-15-6 cyclohexyl-bis-oxiranylmethyl-amine 
• 134744-84-6 1-Cyclohexylamino-3-(5-phenyl-4H-[1,2,4]triazol-3-ylsulfanyl)-propan-2-ol 
• 134744-85-7 1-(5-Benzyl-4H-[1,2,4]triazol-3-ylsulfanyl)-3-cyclohexylamino-propan-2-ol 
• 134744-88-0 1-Cyclohexylamino-3-(5-pyridin-3-yl-4H-[1,2,4]triazol-3-ylsulfanyl)-propan-2-ol 
• 134744-86-8 1-Cyclohexylamino-3-(5-phenoxymethyl-4H-[1,2,4]triazol-3-ylsulfanyl)-propan-2-ol 
• 134744-87-9 1-Cyclohexylamino-3-(5-pyridin-4-yl-4H-[1,2,4]triazol-3-ylsulfanyl)-propan-2-ol 
• 61269-13-4 3-(3-cyclohexylamino-2-hydroxy-propoxy)-4,5α-epoxy-17-methyl-morphin-7-en-6α-ol 

Relevant academic research and scientific papers

Synthesis of Different Classes of Six-Membered Gold(I) NHC Complexes by the Isonitrile Route

Different types of six-membered N-heterocyclic gold carbene complexes were prepared by using gold(I) isonitrile complexes as precursors in combination with suitably functionalized amines. The simple procedures provide an easy access to not only unsymmetrically substituted saturated carbene complexes but rarely reported types of carbene complexes such as six-membered N-heterocyclic oxo-carbene complexes, and six-membered partly unsaturated ligands can be obtained following the strategy.

Synthesis and cytotoxic activity of new isothiazolo[5,4-d]pyrimidine derivatives

The synthesis of new 5-amino-3-methylisothiazolo[5,4-d]pyrimidines series is reported. The cytotoxic activity of these compounds has been determined on the two tumor cell lines (P-388 and KB). Two representative compounds 7 and 8 displayed a significant c

Preparation of Trimethylsilyl Ethers of 3-Azetidinols . Scope and Limitations

Preparation of the trimethylsilyl ethers of 1-alkyl-3-azetidinols from-non-hindered primary amines and epichlorhydrin by conversion of the intermediate 1-(alkylamino)-3-chloro-2-propanols to their trimethylsilylethers by either N-(trimethylsilyl)acetamide or by 1-(trimethylsilyl)imidazole followed by ring closure in acetonitrile is described.This sequence of reactions fails for aromatic amines, but appears to be general for all primary aliphatic amines, although the condensation of hindered amines with epichlorhydrin occurs slowly.Several novel azetidinols, in which the N-alkyl substituent insefl contains a second heterocyclic system, are reported.In addition, the pKA's of several m- and p-substituted 1-benzylazetidinols correlates well with the Hammett equation.